Change of the host immune response during the early phase of interferon therapy correlates with its long-term efficacy for chronic hepatitis C

Momosaka, Yasuhiro; Yamada, Shinwa; Harada, Yuji; Mine, Shinichiro; Tsuchiya, Y.; Okubo, Hideo; Eto, Sumiya

doi:10.1016/s1386-6346(00)00094-2

Hepatology Research

2001

DOI: 10.1016/s1386-6346(00)00094-2

|View full text |Cite

Change of the host immune response during the early phase of interferon therapy correlates with its long-term efficacy for chronic hepatitis C

Yasuhiro Momosaka

Shinwa Yamada

Yuji Harada

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2003

2006

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been reports that ICAM-1 is produced and secreted by tumor cells and that sICAM-1 may be used as a marker for disease progression and prognosis in patients with HCC [6,8] . Furthermore, there have been reports of a relationship between the effi cacy of interferon therapy and sICAM-1 in patients with hepatitis C virus (HCV) RNA positive (C-viral) chronic hepatitis (CH) or liver cirrhosis (LC) [9,10] . As mentioned above, many studies were performed recently to determine the relationships between sICAM-1 concentrations and progression of hepatitis and hepatocarcinogenesis.…”

mentioning

confidence: 99%

Measurement of Human Intercellular Adhesion Molecule 1 in the Blood Is Useful for Predicting the Occurrence of Hepatocellular Carcinomas from Chronic Hepatitis C and Liver Cirrhosis

Moriyama

Matsumura²,

Shioda³

et al. 2006

Intervirology

View full text Add to dashboard Cite

Objective: We measured the concentrations of serum intercellular adhesion molecule 1 (sICAM-1) in patients with C-viral chronic liver diseases and started prospective studies immediately thereafter, in order to determine whether the concentration of sICAM-1 is useful for predicting the occurrence of hepatocellular carcinoma (HCC) following C-viral chronic hepatitis (CH) and liver cirrhosis (LC). Methods: We studied 74 patients with CH, 18 with LC, and 28 patients with HCC who visited our institute from 1993 through 1996. All were positive for hepatitis C virus RNA in the blood. The concentrations of sICAM-1 were measured using enzyme-linked immunosorbent assay kits. The expression of ICAM-1 in the liver was detected by indirect immunoperoxidase staining. Results: The concentrations of sICAM-1 were significantly higher in patients with LC and HCC than in patients with CH. The sICAM-1 concentrations were high in patients whose platelet counts were low. ICAM-1 in the liver was localized to the endoplasmic reticulum or the membrane of cancer cells. The cumulative rate of occurrence of HCC from CH or LC was significantly higher in the high-sICAM-1 group (>400 ng/ml) than in the low-sICAM-1 group. Multivariate analysis revealed that elevation of the sICAM-1 concentration is a significant risk factor for the occurrence of HCC. Conclusion: Evaluation of the sICAM-1 concentration is useful for prediction of the occurrence of HCC in patients with C-viral CH or LC.

show abstract

mentioning

confidence: 99%

Measurement of Human Intercellular Adhesion Molecule 1 in the Blood Is Useful for Predicting the Occurrence of Hepatocellular Carcinomas from Chronic Hepatitis C and Liver Cirrhosis

Moriyama

Matsumura²,

Shioda³

et al. 2006

Intervirology

View full text Add to dashboard Cite

show abstract

Circulating Intercellular Adhesion Molecule-1 in Chronic Hepatitis C Patients with Normal or Elevated Aminotransferase before and after Alpha-Interferon Treatment

Montalto

Giannitrapani²,

Soresi³

et al. 2003

Intervirology

View full text Add to dashboard Cite

Objectives: Intercellular adhesion molecule-1 (ICAM-1) plays a fundamental role during liver inflammation. In fact, weak ICAM-1 expression is physiologically restricted to the endothelium of portal vessels and to sinusoidal lining cells, but it becomes markedly evident on sinusoidal lining cells and at the surface of hepatocytes during inflammatory liver diseases. The aim of this study was to evaluate the behaviour of soluble ICAM-1 (sICAM-1) in chronic hepatitis C (CH-C) patients with persistently normal aminotransferase in comparison with patients with CH-C and elevated aminotransferase, and its changes during α-interferon (IFN) therapy. Immunohistochemical localization of ICAM-1 was also performed on liver tissue specimens of both groups. Methods: Sixty subjects were divided into 3 groups: group A included 19 patients with CH-C and persistently normal aminotransferase; group B included 21 patients with CH-C and persistently elevated aminotransferase levels, and group C included 20 healthy subjects representing the control group. The first two groups were treated with recombinant α-IFN 2b at a dose of 6 MU 3 times a week for 3 months and followed up with 3 MU 3 times a week for another 3 months. Results: Baseline values of serum ICAM-1 in groups A and B were significantly higher than those in group C (p < 0.0001). The median baseline value of sICAM-1 in group A (525.0 ng/ml) was lower than that of group B (561.0 ng/ml), but the difference was not statistically significant. Furthermore, there was a trend toward higher ICAM-1 values as histological severity increased (Mantel-Haenszel χ² 8.8, p < 0.003). Post-treatment sICAM-1 serum values showed a marked decrease in both groups, but only among responder patients, while ICAM-1 levels were unchanged in non-responders. Immunohistochemical localization showed no staining for ICAM-1 in normal liver specimens, while there was a quite similar staining for ICAM-1 in the two groups of patients, consistent with an inflammatory process. Conclusions: This study shows that circulating ICAM-1 levels in most patients with CH-C and persistently normal aminotransferase are higher than those in a control group and the fact that ICAM-1 molecules are also expressed on the hepatocyte membrane suggests that they could play an important role, in association with other molecules, in the intercellular adhesion processes during the induction and maintenance phases of the immune response. In both groups, only patients responding to α-IFN therapy showed a marked decrease in serum ICAM-1 below baseline values.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Change of the host immune response during the early phase of interferon therapy correlates with its long-term efficacy for chronic hepatitis C

Cited by 2 publications

References 29 publications

Measurement of Human Intercellular Adhesion Molecule 1 in the Blood Is Useful for Predicting the Occurrence of Hepatocellular Carcinomas from Chronic Hepatitis C and Liver Cirrhosis

Measurement of Human Intercellular Adhesion Molecule 1 in the Blood Is Useful for Predicting the Occurrence of Hepatocellular Carcinomas from Chronic Hepatitis C and Liver Cirrhosis

Circulating Intercellular Adhesion Molecule-1 in Chronic Hepatitis C Patients with Normal or Elevated Aminotransferase before and after Alpha-Interferon Treatment

Contact Info

Product

Resources

About